Details of Disease

General Information of Disease (ID: DIS1UUNY)

Disease Name	Malnutrition
Synonyms	malnutrition; malnourished
Disease Class	5B50-5B71: Nutritional deficiency
Definition	A condition produced by dietary or metabolic deficiency. The term includes all diseases caused by an insufficient supply of essential nutrients, i.e., protein (or amino acids), vitamins, and minerals. It also includes an inadequacy of calories. (From Dorland, 27th ed; Stedman, 25th ed)
Disease Hierarchy	DIS0W6QK: Nutritional disorder DIS1UUNY: Malnutrition
ICD Code	ICD-11 ICD-11: 5B50-5B71 Expand ICD-9 2.60E+29
Disease Identifiers	MONDO ID MONDO_0006873 MESH ID D044342 UMLS CUI C4761312 MedGen ID 1677627 HPO ID HP:0004395 SNOMED CT ID 47563007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adenine	DMZLHKJ	Approved	Small molecular drug	[1]
Adenosine monophosphate	DMNIJT0	Approved	Small molecular drug	[2]
Adenosine triphosphate	DM79F6G	Approved	Small molecular drug	[3]
Cyproheptadine	DM92AH3	Approved	Small molecular drug	[4]
Gamma-Homolinolenic acid	DMSXKYG	Approved	Small molecular drug	[5]
Glycine	DMIOZ29	Approved	Small molecular drug	[6]
L-Phenylalanine	DMQXI9F	Approved	Small molecular drug	[7]
L-Proline	DMKSTWR	Approved	Small molecular drug	[8]
L-Tyrosine	DM9O8DT	Approved	Small molecular drug	[9]
Nadrolone phenylpropionate	DMZVLY8	Approved	Small molecular drug	[10]
Pyridoxal Phosphate	DMO2K0J	Approved	Small molecular drug	[11]
Pyruvic acid	DM7Q41G	Approved	Small molecular drug	[12]
Safflower Oil	DMO637Y	Approved	NA	[13]
Succinic acid	DMDWICP	Approved	Small molecular drug	[14]
Tetrahydrobiopterin	DMINZ4W	Approved	Small molecular drug	[15]
Tetrahydrofolic acid	DMH15UV	Approved	Small molecular drug	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 Drug(s)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-07258669	DM3CJ5N	Phase 1	Small molecule	[17]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4788).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2455).
3	Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
4	Cyproheptadine FDA Label
5	Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 1993 Nov 1;119(9):867-73.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 727).
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3313).
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3314).
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4791).
10	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5249).
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4809).
13	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3637).
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5276).
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4675).
17	ClinicalTrials.gov (NCT04628793) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF PF-07258669 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.